Cell-based therapies are associated with risks that need to be understood and quantified in order to develop treatments with an acceptable level of safety.
panCELLa offers a solution: a FailSafe Cell System.
One of the biggest concerns with cell-based therapies is safety, in particular the concern of inducing malignant growth originating from the graft. In vitro cell expansion is open to the generation of abnormal cells; a cell culture is a competitive environment, in which the better surviving and faster dividing cells can take over the culture very rapidly. Increased growth rate in cell culture is frequently the consequence of the same genetic or epigenetic changes also associated with cancer. Stem cells could remain among the therapeutic cells, which could also develop into tumours, called teratomas. Therefore, the safety of iPS and ES cell-based therapies is complex and a huge concern. panCELLa’s FailSafe Cell Therapy addresses these concerns.
Previous attempts to address the safety issue have employed suicide genes that are used to kill the cells
with a specific drug. The suicide gene has to be reliably expressed or problems can develop:
cells can shut down the expression of transgenes, even if inserted in “permissive” locations
in the event of a deletion or mutation the suicide gene can be lost
In order to obtain a reliable expression of the suicide gene, panCELLa links its expression to a cell division essential locus (CDEL), in this way, if the cell is proliferating, it will be forced to express the suicide gene as well, making it more susceptible and allowing the clinician greater control. The FailSafe Cell System is even more unescapable, as a homozygous link is created, with both alleles of the CDEL carrying a suicide gene.
panCELLa’s exclusive FailSafe Cell System uses a suicide gene (HSV-TK) and an FDA-approved prodrug (Gancivlovir).
An example of CDEL is the CDK1 locus. CDK1 (cyclin-dependent kinase 1) is a critical element of the cell cycle, unlike other members of the CDKs family, its function cannot be replaced by any other protein, and without CDK1 cells are unable to divide.
Through precise genetic engineering, HSV-TK is inserted in the 3’-end of the CDK1 coding sequence, the two genes are transcribed as a single mRNA and two separate proteins are produced due to a 2A linking sequence. In this configuration, the expression of HSV- TK is linked to cell division, and administration of GCV kills all the proliferating cells, leaving non-dividing cells intact. This system has been proved to be effective both in-vitro and in-vivo.
Pluripotent stem cells engineered with the FailSafe Cell System are still capable of differentiation in a multitude of potential therapeutic cell types, showing that the FailSafe Cell System does not interfere with their properties.
With a suicide gene placed in a locus essential for cell-life, all the transplanted cells can be eliminated regardless of their proliferative status. The FailSafe Cell System ensures that cell-based therapies are safe for patients and enables practitioners to control the persistence of cells after transplantation.
A therapeutic batch of cells are considered FailSafe Cells if all of the cells have a functional suicide gene.
The FailSafe Level (FSL) is the odds of receiving a non- FailSafe Cell batch. For example, one out of one thousand (FSL=1,000) or one out of one million (FSL=1,000,000).
panCELLa technology allows one to provide a precise definition of safety and to quantify the safety level of a prospective cell therapy.
The integration of the FailSafe Cell System in cell therapies will be critical for regulators, clinicians and patients to make informed decisions.
To make your cell therapy a FailSafe Cell Therapy, contact panCELLa today.